» Articles » PMID: 31995079

The Urokinase Plasminogen Activator Binding to Its Receptor: a Quantum Biochemistry Description Within an In/homogeneous Dielectric Function Framework with Application to UPA-uPAR Peptide Inhibitors

Overview
Specialties Biophysics
Chemistry
Date 2020 Jan 30
PMID 31995079
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Despite being recognized as a therapeutic target in the processes of cancer cell proliferation and metastasis for over 50 years, the interaction of the urokinase plasminogen activator uPA with its receptor uPAR still needs an improved understanding. High resolution crystallographic data (PDB ) of the uPA-uPAR binding geometry was used to perform quantum biochemistry computations within the density functional theory (DFT) framework. A divide to conquer methodology considering a mixed homogeneous/inhomogeneous dielectric model and explicitly taking water molecules into account was employed to obtain a large set of uPA-uPAR residue-residue interaction energies. In order of importance, not only were Phe25 > Tyr24 > Trp30 > Ile28 shown to be the most relevant uPA residues binding it to uPAR, but the residues Lys98 > His87 > Gln40 > Asn22 > Lys23 > Val20 also had significant interaction energies, which helps to explain published experimental mutational data. Furthermore, the results obtained with the uPA-uPAR in/homogeneous dielectric function show that a high dielectric constant value ε = 40 is adequate to take into account the electrostatic environment at the interface between the proteins, while using a smaller value of ε (<10) leads to an overestimation of the uPA-uPAR binding energy. Hot spots of the uPA-uPAR binding domain were identified and a quantum biochemistry description of the uPAR blockers uPA and cyclouPA[(S21C;H29C)] was performed, demonstrating that cyclization improves the stability of mimetic peptides without compromising their binding energies to uPAR.

Citing Articles

Alzheimer's Disease Immunotherapy and Mimetic Peptide Design for Drug Development: Mutation Screening, Molecular Dynamics, and a Quantum Biochemistry Approach Focusing on Aducanumab::Aβ2-7 Binding Affinity.

Franca V, Bezerra E, da Costa R, Carvalho H, Freire V, Matos G ACS Chem Neurosci. 2024; 15(19):3543-3562.

PMID: 39302203 PMC: 11450751. DOI: 10.1021/acschemneuro.4c00453.


Investigation of protein-protein interactions and hotspot region on the NSP7-NSP8 binding site in NSP12 of SARS-CoV-2.

Lima Neto J, Bezerra K, Barbosa E, Araujo R, Galvao D, Lyra M Front Mol Biosci. 2024; 10:1325588.

PMID: 38304231 PMC: 10830813. DOI: 10.3389/fmolb.2023.1325588.


Quantum Biochemistry and MM-PBSA Description of the ZIKV NS2B-NS3 Protease: Insights into the Binding Interactions beyond the Catalytic Triad Pocket.

Junior V, van Tilburg M, Morais P, Maia Junior F, Lima E, Oliveira V Int J Mol Sci. 2022; 23(17).

PMID: 36077486 PMC: 9456192. DOI: 10.3390/ijms231710088.


Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease.

Amaral J, Oliveira J, Lopes F, Freitas C, Freire V, Abreu L J Biomol Struct Dyn. 2021; 40(19):8925-8937.

PMID: 33949286 PMC: 8108194. DOI: 10.1080/07391102.2021.1920464.